Efzofitimod versus placebo in patients with pulmonary sarcoidosis (EFZO-FIT): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Efzofitimod versus placebo in patients with pulmonary sarcoidosis (EFZO-FIT): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. // The Lancet Respiratory Medicine. – URL: https://www.sciencedirect.com/science/article/pii/S2213260026002833?dgcid=rss_sd_all
Efzofitimod versus placebo in patients with pulmonary sarcoidosis (EFZO-FIT): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine. https://www.sciencedirect.com/science/article/pii/S2213260026002833?dgcid=rss_sd_all
“Efzofitimod versus placebo in patients with pulmonary sarcoidosis (EFZO-FIT): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.” The Lancet Respiratory Medicine.
@article{article32732,
title = {Efzofitimod versus placebo in patients with pulmonary sarcoidosis (EFZO-FIT): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial},
journal = {The Lancet Respiratory Medicine},
url = {https://www.sciencedirect.com/science/article/pii/S2213260026002833?dgcid=rss_sd_all}
}